- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02110797
Osteoporosis in RETT Syndrome (OSRETT)
Osteoporosis in RETT Syndrome. Understanding the Mechanisms and Identification of Biomarkers.
Based on our clinical observations, many girls with RETT syndrome, a severe neuro-developmental encephalopathy, suffer from osteoporosis which can appear at a very early age (before age 10) and can lead to fractures, pain and a limitation in mobility. Few epidemiological studies have estimated the frequency of osteoporosis in girls with RETT syndrome and showed that they are more exposed then children with other neuro-developmental diseases with a same degree of neurological handicap. However, the mechanisms that lead to early osteoporosis in RETT syndrome remain unknown. Mutations in the MECP2 gene are found in 95% of RETT patients and preliminary experimental studies have shown that this can lead to abnormal expression of the gene that codes for osteoprotegerin, a protein implicated in bone remodelling by interacting with RANK-ligand.
In order to identify risk factors of osteoporosis in RETT syndrome and to understand the pathophysiological mechanisms the study protocol includes:
- Clinical evaluation of bone health (history of bone fractures, pain, nutritional status, pubertal stage, daily caloric/calcium intake, anti-epileptic drugs, walking ability, vitamin D satus)
- evaluation of the mineral density at the lumber spine using DEXA
- measuring concentrations of osteoprotegerin and RANK-ligand
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Based on our clinical observations, many girls with RETT syndrome, a severe neuro-developmental encephalopathy, suffer from osteoporosis which can appear at a very early age (before age 10) and can lead to fractures, pain and a limitation in mobility. Few epidemiological studies have estimated the frequency of osteoporosis in girls with RETT syndrome and showed that they are more exposed to osteoporosis then children with other neuro-developmental diseases with a same degree of neurological handicap. However, the mechanisms that lead to early osteoporosis in RETT syndrome remain unknown.
Mutations in the MECP2 gene are found in 95% of RETT patients. Preliminary experimental studies on the transcriptional consequences of MECP2 mutations showed that the expression of 13 genes were significantly dysregulated and one of them is the gene that codes for osteoprotegerin, a soluble receptor that binds to RANK-ligand. RANK-ligand is an osteoclastic differentiation factor expressed by osteoblasts.
In order to identify risk factors of osteoporosis in RETT syndrome and to understand the pathophysiological mechanisms the study protocol includes:
- Clinical evaluation of bone health (history of bone fractures, pain, nutritional status, pubertal stage, daily caloric/calcium intake, anti-epileptic drugs, walking ability, vitamin D status)
- evaluation of the mineral density at the lumber spine using DEXA
- measuring concentrations of osteoprotegerin and RANK-ligand
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bicêtre, France, 94275
- Kremlin Bicêtre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- RETT syndrome
- MECP2 mutation
Exclusion Criteria:
- no identified MECP2 mutation
- history of drugs that interfere with bone metabolism
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: RETT patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
osteoporosis in RETT patients
Time Frame: Day 0
|
Correlation between clinical/biological risk factors and mineral density and osteoporosis in RETT patients
|
Day 0
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biological Mechanisms of osteoporosis
Time Frame: Day 0
|
RANK-ligand and osteoprotegerin concentrations
|
Day 0
|
Collaborators and Investigators
Investigators
- Principal Investigator: Agnès Linglart, MD, PhD, Kremlin Bicetre hospital
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Disease
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Musculoskeletal Diseases
- Bone Diseases
- Mental Retardation, X-Linked
- Intellectual Disability
- Heredodegenerative Disorders, Nervous System
- Bone Diseases, Metabolic
- Syndrome
- Osteoporosis
- Rett Syndrome
Other Study ID Numbers
- P071230
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on RETT Syndrome With Proven MECP2 Mutation
-
University of Alabama at BirminghamUniversity of Colorado, Denver; Eunice Kennedy Shriver National Institute of... and other collaboratorsCompletedRett Syndrome, Preserved Speech Variant | Mecp2 Duplication Syndrome | Rett-related DisordersUnited States
-
University of Alabama at BirminghamUniversity of Colorado, Denver; Eunice Kennedy Shriver National Institute of... and other collaboratorsCompletedRett Syndrome | MECP2 Duplication Disorder | Rett-related DisorderUnited States
-
University of Alabama at BirminghamEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedRett Syndrome | CDKL5 Disorder | MECP2 Duplication dIsorder | FOXG1 SyndromeUnited States
-
University Hospital, BrestUnknownDysautonomia | Masculinity | MECP2-Related Severe Neonatal EncephalopathyFrance
-
University of Alabama at BirminghamEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedCDKL5 | Rett Syndrome | MECP2 Duplication | FOXG1 DisordersUnited States
-
Ionis Pharmaceuticals, Inc.RecruitingMethyl CpG Binding Protein 2 (MECP2) Duplication SyndromeUnited States
-
Children's Hospital Medical Center, CincinnatiRecruitingNeurofibromatosis 1 | Noonan Syndrome | Legius Syndrome | Cardiofaciocutaneous Syndrome | Costello Syndrome | SYNGAP1-Related Intellectual Disability | DLG4 | RAS Mutation | Noonan Syndrome With Multiple Lentigines | Noonan Neurofibromatosis Syndrome | Smith-Kingsmore Syndrome | MTOR Gene Mutation | GATOR-1 Gene... and other conditionsUnited States
-
Groupe Francophone des MyelodysplasiesAprea TherapeuticsUnknownChronic Myelomonocytic Leukemia | Myeloproliferative Neoplasm | Acute Myeloid Leukemia With Gene Mutations | Myelodysplastic Syndrome With Gene MutationFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); CelgeneRecruitingAcute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome With Excess Blasts | IDH2 Gene Mutation | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 20-30 Percent of Bone Marrow Nucleated CellsUnited States
-
Simons SearchlightBoston Children's Hospital; Geisinger Clinic; Simons FoundationRecruitingSMARCA4 Gene Mutation | DDX3X | 16P11.2 Deletion Syndrome | 16p11.2 Duplications | 1Q21.1 Deletion | 1Q21.1 Microduplication Syndrome (Disorder) | ACTL6B | ADNP | AHDC1 | ANK2 | ANKRD11 | ARID1B | ASH1L | BCL11A | CHAMP1 | CHD2 | CHD8 | CSNK2A1 | CTBP1 | CTNNB1 Gene Mutation | CUL3 | DNMT3A | DSCAM | DYRK1A | FOXP1 | GRIN2A | GRIN2B | HIVEP2-Related Intellectual... and other conditionsUnited States
Clinical Trials on biological markers and evaluation of the mineral density at the lumber spine using DEXA
-
Centre Hospitalier Universitaire de NīmesCompleted
-
University Medical Centre LjubljanaCompletedFood AllergySlovenia
-
University of DerbyRecruitingOld Age; Debility | Stability | Balance; DistortedUnited Kingdom
-
Anchora MedicalRecruiting
-
Madigan Army Medical CenterUnknownLow Back Pain | Myofascial Pain Syndrome Lower BackUnited States